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Two decades of molecular, cellular, and functional studies considerably increased our understanding of dystrophins function and
unveiled the complex etiology of the cognitive deﬁcits in Duchenne muscular dystrophy (DMD), which involves altered expression
of several dystrophin-gene products in brain. Dystrophins are normally part of critical cytoskeleton-associated membrane-bound
molecular scaﬀolds involved in the clustering of receptors, ion channels, and signaling proteins that contribute to synapse
physiology and blood-brain barrier function. The utrophin gene also drives brain expression of several paralogs proteins, which
cellular expression and biological roles remain to be elucidated. Here we review the structural and functional properties of
dystrophins and utrophins in brain, the consequences of dystrophins loss-of-function as revealed by numerous studies in mouse
models of DMD, and we discuss future challenges and putative therapeutic strategies that may compensate for the cognitive
impairment in DMD based on experimental manipulation of dystrophins and/or utrophins brain expression.
1.Introduction
When dystrophin was identiﬁed as the protein responsible
for the X-linked Duchenne muscular dystrophy (DMD)
syndrome [1], we were far from expecting a role for
this protein in a variety of tissues including the central
nervous system (CNS). Dystrophin is a large 427-kDa
cytoskeleton-associated membrane-bound protein, in which
loss-of-function in striated muscles results in membrane
instability with progressive, severe, and fatal muscle degen-
eration in about 1/3000 newborn males. Dystrophin is
a key component of multiprotein complexes (dystrophin-
associated glycoprotein complex, or DGC) located at the
plasma membrane in both muscle and nonmuscle tissues,
which mediate interactions between the cytoskeleton, cell
membrane, and extracellular matrix (ECM). DGCs are
involved in signaling pathways that regulate the structural
organization of specialized membrane-contact zones, in
particular the clustering of ion channels and postsynaptic
membrane receptors during synaptogenesis. The presence of
dystrophin and DGC in central synapses in brain regions
involved in cognitive functions suggeststhat loss-of-function
may be responsible for the cognitive deﬁcits and mental
retardation associated with DMD.
Two decades of research signiﬁcantly increased our
understanding of dystrophin function and unveiled the
complex etiology and multisystemic aspect of the brain
and cognitive alterations in DMD. The rapid development
of molecular tools and antibodies directed against speciﬁc
domains of the protein led to the discovery of an array
of dystrophin-gene products. In brain, each of these dys-
trophins is expressed from distinct internal promoters in
either neurons or astrocytes and is component of distinct
DGCs selectively involved in synapse or blood-brain barrier
(BBB) functions. While the loss of full-length dystrophin is
a common feature in all DMD patients and may explain
some of the mild deﬁcits displayed across intellectual levels
[2], the presence of mental retardation in a subpopulation of2 Journal of Biomedicine and Biotechnology
patients likely results from mutations aﬀecting expression of
shorter dystrophin-gene products derived from downstream
promoters,suchasDp140andDp71[3].Onemainchallenge
to understand the clinical heterogeneity in DMD is to
decipher the speciﬁc roles of the diﬀerent dystrophins in the
genesis of cognitive impairments. Moreover, a large number
of dystrophin paralogs encoded by distinct autosomal genes,
such as the utrophin-gene products, have also been charac-
terized in CNS, thus showing that dystrophins are members
of a large and complex superfamily of membrane-bound
cytoskeletal proteins. While these paralogs are not directly
involved in known genetic diseases, they likely subserve
important cellular functions and may oﬀer new prospects
in the search of compensatory strategies to alleviate the
cognitive phenotype in DMD.
This review summarizes our current knowledge of
the structural and functional properties of dystrophins,
utrophins and DGCs in brain, as well as the mechanisms
by which they participate to the genesis of brain and
cognitive alterations in DMD. A detailed description of their
expressionand/orfunctioninmuscles,retina,orinvertebrate
nervous system falls outside the scope of the review and can
befoundelsewhere[4–6].Rather,inthefollowingdiscussion
we will ﬁrst detail the cognitive proﬁle of DMD patients
and the genotype-phenotype relationships linking cognitive
impairments to brain dystrophins. Then we will focus
on the main structural and functional commonalities and
diﬀerences between the dystrophin-gene and utrophin-gene
products in the mammalian brain, as this may be relevant
fortherapeuticstrategies.Wewilldetailhowrecentstudiesof
dystrophins loss-of-function in mouse models of DMD have
led to a broader understanding of the neurobiology of the
disease, and for the utrophin-gene products, we will show
how analyses of their structure, their interactions with the
DGC, and their cellular and subcellular distribution helped
proposing hypotheses on their function in brain tissues. In
the last part of the discussion we will describe the recent
advances made to treat muscle pathology in DMD, mostly
based on the manipulation of dystrophins and utrophins
expression, and we will highlight the future challenges
and therapeutic strategies that may help translating these
approaches to alleviate the cognitive impairment in DMD.
2.The CognitiveImpairmentinDMD
DMD is associated with nonprogressive mild to severe
cognitive deﬁcits and poor academic achievement, which
are independent from the muscular handicap or clinical
environment [7]. Full-scale intelligence quotient (IQ) scores
of DMD patients are distributed normally, in accordance
with the assumption that the cognitive defect results from
the same mutations that cause myopathy. However, a
one standard-deviation leftward shift of the distribution
results in a reduced mean IQ (80–85) compared to the
normal population mean of 100 [8]. In fact, about one
third of DMD boys have IQ scores below 70 and display
mental retardation (MR). Deﬁcits aﬀect both receptive
and expressive language skills, with alterations in auditory
comprehension, phonological knowledge and language, and
delayed acquisition of reading, which has been partly
attributed to a form of developmental dyslexia, that is,
dysphonetic dyslexia [9]. Impaired short- and long-term
memory performances are consistently reported and include
defective recall, working memory, memory span, and visuo-
spatial skills [2, 7, 10, 11]. Recent studies emphasized the
high incidence of various neuropsychiatric disorders, such
as autism spectrum, attention deﬁcits, hyperactivity, and
obsessive-compulsive disorders [12], depression and anxiety
symptoms [10], as well as social behavior problems and poor
recognition of facial aﬀect [13–15]. Thus, DMD involves
a range of neurobehavioral disturbances likely related to
functional alterations in integrated brain circuits including
the cerebellum, hippocampus, and associative cortical areas
[16], in line with dystrophins expression patterns in brain
[17].
3. Genotype-PhenotypeRelationships
It is admitted that the cognitive impairments in DMD
have a genetic basis and that the site of mutations in the
dystrophin gene determines the risk of cognitive deﬁcit.
Genotype-phenotype relationships were initially based on
reportsshowingthatdeletionsofexon52[18]andmutations
aﬀecting the carboxyl terminus of dystrophin [19]w e r e
associated with mental retardation. Conclusions from both
clinical and animal-model studies then converged to the
current hypothesis that all dystrophins expressed in brain
likely contribute to the cognitive and behavioral alterations
in DMD. The presence of moderate but speciﬁc memory and
attention deﬁcits in all DMD patients, regardless of whether
they are of high or low intellectual function [2], suggests
a role for the full-length (Dp427) dystrophin which is
commonly lost in all patients. However, mutations aﬀecting
the genomic region of Dp71 and Dp140 have been associated
with higher incidence and most severe proﬁles of cognitive
alterations [20–22], and these short C-terminal dystrophins
have thus emerged as major contributing factors to the
genesis of mental retardation. The most recent studies using
large cohorts of patients and ﬁne classiﬁcations of subphe-
notypes and dystrophin products conﬁrm these hypotheses:
Mutation location determines cognitive disability, but not
motor outcomes [3]; loss-of-function of all dystrophin-gene
products is systematically associated with severe form of
mental retardation with Dp71 loss being a clear aggravating
factor [23]; correlations between mutation locations and IQs
suggest that the variable degrees of cognitive impairments
result from the cumulative loss of the diﬀerent dystrophin
products [24].
Structure-function analyses and functional studies of
mouse models of DMD (below) provided an essential
contribution to our understanding of the speciﬁc brain
mechanisms involved in the genesis of the cognitive alter-
ations in DMD. They conﬁrmed the implication of Dp427
and Dp71 in brain and cognitive functions and helped
elucidating the selective roles of these distinct dystrophin
products in speciﬁc brain mechanisms.Journal of Biomedicine and Biotechnology 3
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Figure 1: Organization of the human dystrophin (a) and utrophin (b) genes and corresponding protein products. Top panels show speciﬁc
exons (yellow boxes with exon numbers) and intronic regions (black line) ﬂanking transcription start sites of the diﬀerent gene internal
promoters (arrows) (Source: Pubmed: ENSG00000198947 for DMD gene; ENSG00000152818 for utrophin gene). Alternatively spliced ﬁrst
exons giving rise to distinct full-length forms of dystrophin (B: Brain; M: Muscle; P: Purkinje cells) and utrophin (Utrn-A; Utrn-B) are
depicted (adapted from [30]). The diﬀerent dystrophin (a) and utrophin-gene (b) protein products derived from distinct internal promoters
are shown below the corresponding genes, as indicated. The main structural domains are represented, including the speciﬁc NH2-terminus
domain (N, diﬀerent colors schematize distinct NH2-terminal sequences), the central rod domain (green bar), the cysteine-rich domain
(CYS, blue), and the COOH-terminus (red). All gene regions and protein domains are not to scale.
4. Structure and Expressionof
the Dystrophin-GeneProducts
In DMD, the majority of mutations, mainly deletions but
also duplications, inversions and point mutations, are out-
of-frame and result in complete loss of dystrophin or
expression of nonfunctional truncated proteins. However,
someinternallytruncatedproteinsthatonlymisssomeofthe
repeats of the central domain of dystrophin retain functional
activity and are associated with the milder Becker muscular
dystrophy (BMD) phenotype, suggesting that diﬀerent dys-
trophin structural domains have distinct functions [25]. Key
structure-functioncorrelationshavebeencharacterizedfrom
genotype-phenotype studies in DMD patients (e.g., [3, 26])
and from numerous studies in genetic mouse models of
DMD, including forced expression of truncated dystrophin
constructs in dystrophin-deﬁcient mice (e.g. [27]).
4.1. The Full-Length Dystrophin (Dp427). The DMD or dys-
trophin gene, identiﬁed by positional cloning and localized
to Xp21, is the largest described, spanning ∼2.5-Mb with 79
exons encoding a 14kb mRNA transcript. This full-length
mRNA and the corresponding 427-kDa protein, called dys-
trophin or Dp427, are predominantly expressed in skeletal
and cardiac muscles and to a lesser extent in the nervous
system. Dystrophin structure is organized in four main
domains (Figure 1)( [ 4, 28, 29] for reviews). The N-terminal
domain (246 amino-acids) similar to α-actinin contains sev-
eral actin-binding sites and a calmodulin-binding site. The
central rod domain (2840aa) has 24 triple-helical spectrin-
like repeats thought to give the protein a ﬂexible structure,
with several irregular short and long segments, and four
proline-rich end regions. As deletions of this region often
result in mild or no clinical consequences, it is sometimes
simply considered as a spacer between the actin-binding
domain and the next cysteine-rich and COOH-terminal
domains. These latter are of high functional relevance as
they interact with several membrane-bound and cytosolic
proteins that form the DGC (Figure 2): the cysteine-rich
domain (280aa) participates in the critical interaction of
dystrophin with the transmembraneous DGC component,
β-dystroglycan. It starts with a WW domain described as a
protein-binding module, followed by two calcium-binding
EF-hand motifs and a zinc-ﬁnger ZZ domain representing a
functional calcium-dependent binding site for calmodulin.
The COOH-terminus (320aa) is an α-helical coiled coil
region that binds to the cytosolic component dystrobrevin
and may also modulate interactions with syntrophins and
other DGC-associated proteins.
Several phosphorylation sites have been identiﬁed within
dystrophinstructuraldomains,suggestingregulationofactin
binding by endogeneous protein kinases (PK) such as PKA,
PKC, calmodulin kinase II (CamKII), and casein kinase
II (CKII) [31–33], while interactions with the DGC and
signaling proteins could be modulated by CamKII, CKII,
MAPK, cdc2, and GSK-3 [34–36].
4.2.Tissue-SpeciﬁcPromotersDriveExpressionofDistinctDys-
trophins. At least seven internal promoters enable expres-
sion of several dystrophin-gene products in a tissue and
cell-speciﬁc manner (Figure 1). Dp427 is derived from
three independent promoters (M, B, and P) consisting of
spliced unique ﬁrst exons that regulate the spatiotemporal
expression of this full-length protein in muscles, forebrain
structures, and cerebellar Purkinje cell, respectively. In adult
skeletal muscle, Dp427 is located at the sarcolemma and
in the troughs of the postsynaptic membrane. Its loss is
associated with disruption of membrane integrity, protease4 Journal of Biomedicine and Biotechnology
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Figure 2: Organization and composition of the dystrophin/utro-
phin-associated glycoprotein complexes (DGC/UGC). The NH2-
terminus of dystrophins and utrophins (purple) binds to cytoskele-
tal ﬁlamentous actin (F-actin) while the cysteine-rich and COOH
domains interact with the diﬀerent DGC/UGC components. The
cysteine-rich domain binds the dystroglycan subcomplex com-
posed of transmembrane β-dystroglycan (β-DG) and extracellular
α-dystroglycan (α-DG). The β-dystroglycan may interact with
the sarcoglycan-sarcospan subcomplex (blue) and with signaling
protein such as Grb2. The α-DG is a glycosylated receptor for
extracellular matrix proteins, such as laminin, agrin, perlecan,
and neurexin depending on tissue- and cell-speciﬁc expression.
The COOH-terminus of dystrophins/utrophins binds the cytosolic
proteins syntrophins and dystrobrevins. Dystrobrevins associate
with syncoilin, dysbindin, and syntrophins (SYN). Syntrophins
contain a PDZ domain enabling associations of the DGC with a
variety of proteins including signaling and synaptic proteins, such
as neuronal nitric oxide synthase (nNOS) or neuroligins, as well
as several transmembrane channels (AQP-4, potassium Kir2 and
Kir4.1, and voltage-gated sodium channels) and receptors (AchR,
GABAAR).
activation, calcium inﬂows, and altered calcium homeostasis
leading to progressive muscle necrosis and wasting (reviewed
in [4, 37]). In brain and cerebellum, Dp427 is mainly
detected along plasma membranes in the soma and in the
postsynaptic densities (PSDs), specialized regions of the
synapsesubmembraneouscytoskeletonofprincipalneurons.
Several studies provided evidence for major expression in
brain regions involved in motor, emotional, and cognitive
functions ([38] for a review), such as the hippocampus,
neocortex, cerebellum, and amygdala, whereas little or no
dystrophin could be detected in other subcortical regions
such as striatum, thalamus, and hypothalamus [17, 39, 40].
Therefore,Dp427 loss-of-functionisacommonfeatureinall
DMD patients that may result in both muscle degeneration
and altered brain function.
Four shorter nonmuscle products expressed from down-
stream promoters have been characterized, which in com-
mon with Dp427 harbor at least the cysteine-rich and
COOH-terminal domains. They have been named according
to their respective molecular weights: Dp260 (Dystrophin
protein of 260kDa) is found in the outer plexiform layer in
the retina and its dysfunction is associated with alterations
of the electroretinogram and of color vision [41, 42]. Dp140
is detected in kidneys, retina, and brain; it is abundant in
fetalbraintissuesandisthoughttobeessentiallyexpressedin
astrocytesand/ormicrovasculature[43,44].Dp116ismainly
expressed in Schwann cells in spinal cord [45], yet it has also
been detected in brain PSDs [46]; The short Dp71 product is
transcribed from a promoter located between exons 62 and
63 and has a unique N-terminus of seven amino acids. It is
detected in cardiac muscle and in most nonmuscle tissues
including brain, retina, kidney, liver, and lung. It is the most
abundant DMD-geneproduct in adult CNS, mainly detected
around brain blood vessels in perivascular astrocyte endfeet
[47], suggesting a role in BBB function. Dp71 mRNA is also
detected in neurons in olfactory bulb and in the dentate
gyrus of the hippocampus [48]; the protein is found in
cultured neurons [49] and in the PSDs of central synapses
in the adult brain [50, 51], suggesting an additional role in
synaptic function.
Expression of DMD-gene products also appears to be
modulated during development and in diﬀerent tissues by
alternative splicing at the 3  end of the gene, which generates
anevengreaternumberofdystrophinisoforms[52].Splicing
preferentially aﬀects four tandems of exons (71–74) and
exon 78 in Dp427, Dp140, and Dp71 [28, 53–57]. While
all DMD-gene products retain functional cysteine-rich and
COOH-terminaldomainsandcanthereforeinteractwiththe
DGC, the splicing of exons 71–74 seems to be of functional
importance as it likely modulates the capacity of dystrophins
to bind speciﬁc components of the DGC such as syntrophins
[51, 58].
Thus, the dystrophins constitute a family of cytoskeleton
proteinswithmultipleproductsofvariousmolecularweights
and spliced variants, each of which is a central component
of a membrane-bound molecular scaﬀold. These proteins
have speciﬁc sequences but high structural homologies and
may therefore endorse cell-speciﬁc roles as well as common
biological functions.
5. Structure and Expressionof
Dystrophin-RelatedProteins
Dystrophins share structural homology with a range of
paralog proteins called the dystrophin-related proteins, such
as utrophin, DRP2, dystrobrevin, and dystrotelin [59]. The
utrophin family of proteins has been most studied due to
its involvement in skeletal muscle development and function
at the adult neuromuscular junction (NMJ). Because dif-
ferent utrophin-gene products derive from distinct internal
promoters in a variety of tissues, as for expression of the
diﬀerent dystrophin-gene products, their potential role in
compensating dystrophin deﬁciency in DMD has yielded
much interest in recent research.Journal of Biomedicine and Biotechnology 5
5.1. The Full-Length Utrophin. This autosomal protein was
identiﬁed in 1989 [60] due to its large homology with
dystrophin, and it was named utrophin because of its
ubiquitoustissueexpressionascomparedtodystrophin[61].
The gene is localized on human chromosome 6q24 [62]
and on mouse proximal chromosome 10 [61]. This large
900kb gene encodes a 13kb transcript of 74 exons that
predicts a full-length protein of 395kDa, which is therefore
smaller than dystrophin. The primary sequence and protein
structure show large and clear similarities with dystrophin.
The N-terminal domain encompasses the ﬁrst 250aa and
binds F-actin with a similar aﬃnity as dystrophin. Although
being larger and more eﬀective than the dystrophin actin-
binding domain [63], its structure is also comparable to
that of spectrin and alpha-actinin and the actin-binding
process is regulated by calcium and calmodulin. Along with
the cysteine-rich and C-terminal domains, this region shares
80% of identity with the equivalent domain of dystrophin.
The large rod domain is the least conserved region between
the two proteins (35%) (reviewed in [64]), consisting of
22 spectrin-like repeats in utrophin, versus 24 repeats in
dystrophin, and proline-rich hinge regions. The utrophin
C-terminal domain is very similar to that of dystrophin
with typical binding to the diﬀerent DGC members, β-
dystroglycan, α-dystrobrevin, and the syntrophins [4, 5].
Like dystrophin, the utrophin gene harbors tissue-
speciﬁc promoters (Figure 1). Transcription of the full-
length utrophin (Up395) is driven by two independent
promoters, Utrn-A and Utrn-B, coactivated in a number
of tissues but independently regulated. The TATA-box less
Utrn-A promoter is associated with a CpG island and
contains a consensus N-box at the 5  end of the transcript
[65]. The Utrn-B promoter is located in intron 2 of the gene
[66]. Each promoter induces a spliced unique ﬁrst exon but
both promoters drive expression of 13-kb mRNAs which
only diﬀer within the 5 -end region.
The Utrn-A protein is the main isoform in adult skeletal
muscles, enriched at the crest of postsynaptic-membrane
folds in association with acetylcholine receptors (AchR) at
the NMJ. In contrast, Utrn-B is found in muscle vascular
endothelium [67, 68]. Obviously, dystrophin and utrophin
display distinct subcellular localization in adult-striated
muscles. However, utrophin expression occurs before that
of dystrophin in developing and regenerating muscle, where
it is detected along the muscle sarcolemma [69]. At birth
and/or in mature muscle, utrophin is then replaced by
dystrophin along the sarcolemma and its expression remains
conﬁned to NMJ and vasculature [70]. For this reason,
utrophinhasbeenconsideredafoetaldystrophinhomologue
indevelopingmuscletissues,suggestingthatthetwoproteins
could share common functions in muscle structure and/or
physiology.
Full-length utrophins are also detected in nonmuscle
tissues, such as in the CNS, peripheral nerves, testis, kidney,
spleen, liver, lung, platelets, and in small arteries and
veins [71–74]. They are found in both blood vessels and
neurons in the adult brain [75, 76] and in M¨ uller glial
cells in the retina [77]. In neurons, utrophin labelling is
localized along the somatic and dendritic membrane, which
is at variance with the punctuate synaptic staining revealed
by antidystrophin antibodies in synapses [39, 76]. The
respective distributions of Utrn-A and B in the brain have
been recently speciﬁed [78]: Utrn-A is mainly found in
neuronal cells in various brain structures including olfactory
bulb, cortex, medial septum, hypothalamus, hippocampus,
cerebellum, and brainstem nuclei; it is also detected in pia
mater of the meninge, choroid plexus, ependymal lining,
and in some glial cells and vascular structures. Utrn-B is
expressed to a lesser extent in the same brain regions and
seems enriched in vascular elements.
5.2. The Short Utrophin-Gene Products. As for the DMD
gene, the utrophin gene has internal promoters and shorter
protein products (Figure 1) and is also modulated by alter-
native splicing [79, 80]. G-utrophin, or Up113, was the ﬁrst
shortproductidentiﬁedasastructuralhomologueofDp116.
Its 5,5kb transcript predicts a protein composed of the last
twoandahalfcoiled-coilrepeatsoftheroddomain,followed
by the cysteine rich and C-terminal domains of utrophin.
Up113 mRNA diﬀers from that of utrophin at the same
point that Dp116 diverges from dystrophin, that is, intron
55. Up113 and Dp116 share a consensus phosphorylation
site for PKC in the N-terminal domain [79]. Up113 is the
major product of the utrophin gene in the adult brain, but
it is also found in the sensory ganglia, testis, and kidney.
The brain transcript was detected in blood vessels and in
some classes of neurons in accessory olfactory bulb, cerebral
cortex, hippocampal formation, brainstem nuclei, amygdala,
hypothalamus, thalamus, and caudate putamen [39, 79].
Up140 and Up71 are homologous to the short dys-
trophins Dp140 and Dp71. They depart from Up395 at
the same point Dp140 and Dp71 diverge from Dp427. No
actin-bindingsiteshavebeencharacterizedintheN-terminal
domain of these proteins, but ability for protein-protein
interactions is preserved [80]. Up71 is translated from a
4kb mRNA commencing in intron 58 and detected in lung,
muscle, kidney, thymus, liver, and brain. The 71kDa protein
displays the same cysteine-rich and C-terminal domains
as Up395 and is detected in peripheral nerve [81]. Up140
derives from a 6,75kb mRNA commencing in intron 41 and
detected in lung, muscle, kidney, thymus, liver, testis, and
brain. The 155kDa protein comprises the last 6 repeats of
the distal rod domain, the cysteine-rich, and the C-terminal
domainsofUp395.ThefunctionofUp71andUp140inbrain
is unknown.
A short N-terminal utrophin, called N-utrophin, was
described in C6 glioma cells [82]. It is translated from a
3,7kb transcript that predicts a 62kDa protein. This protein
contains the actin-binding domain and two spectrin-like
repeats. Expression in mammalian tissues has not been
demonstrated to date. Other short utrophins have been
reported, such as Up90 in testis, spleen, and liver, Up97 in
testis, Up 109 in the foetal hand and foot dermis, Up103 in
adult testis, and Up120 in kidneys [73, 83].
The presence of short utrophin-gene products with
largely similar structures as compared to dystrophins sug-
gests that duplication of a common ancestor gene might6 Journal of Biomedicine and Biotechnology
haveoccurredaftertheappearanceoftheinternalpromoters.
However, the dystrophin and utrophin genes diverge in their
sequences and speciﬁcities, which results in nonoverlapping
expressionpatterns[59].Strikingly,dystrophinandutrophin
paralogs are generally expressed in distinct brain structures
and cell types, suggesting discrete functions despite high
structural homologies.
5.3. The Other Paralogs. DRP2 and dystrobrevin share
homology with the carboxy-terminal regions of dystrophins
and utrophins. The DRP2 gene is localized to Xq22 and
encodes a 7,7kb transcript corresponding to a 110kDa
protein. Its sequence shares similarity with the cysteine-
rich domain and with the 3  end of the spectrin-like repeat
domainofDp116andUp113[84].DRP2ismainlyexpressed
intheCNSinassociationwithPSDsandcholinergicneurons
[85] and is also detected in the peripheral nervous system
[86]. Dystrobrevin is both a dystrophin paralog and a com-
ponent of the DGC (see below, [87]). The dystrotelin gene
maps on mouse chromosome 1 and human chromosome
2; it encodes a 74-kDa protein that shares homology with
dystrophin and is expressed in the embryonic brain and
neural tube [59].
6.TheUtrophin andDystrophin-Associated
Glycoprotein Complexes
Dystrophin is a key component of the so-called dystrophin-
associated glycoprotein complexes (DGC) (Figure 2)f o r m e d
by at least ten partners encoded by autosomal genes,
including transmembrane (dystroglycans) and cytoplasmic
(syntrophins, dystrobrevins) proteins that link the actin-
based cytoskeleton to the basal lamina in muscles, thus
providing a molecular bridge connecting the inside of the
cell to the extracellular matrix (ECM) ([4, 29, 88]f o r
reviews).FirstidentiﬁedinassociationwithDp427inmuscle
tissues, the DGC interacts with all DMD-gene products
as well as with paralogs of the utrophin family. Emerging
notion conceptualizes the DGC as a scaﬀold for proteins
involved in membrane stabilization and transmembrane
signaling in a variety of tissues and cell types, including
the postsynaptic membrane of neurons in CNS ([5, 89, 90]
for reviews). However, DGC components are diﬀerentially
distributed in distinct brain cell types, where they form
separatedystrophin-likecomplexesthatlikelyharbordistinct
functions (e.g., [50]).
The central part of the DGC is the dystroglycan
subcomplex, composed of α-dystroglycan, an extracellular
glycoprotein of 156kDa in muscles and 120kDa in brain,
and β-dystroglycan, a 43-kDa membrane-spanning glyco-
protein which associates with the cysteine-rich domain of
dystrophins and utrophins. The two proteins are processed
from a precursor protein produced by the dystroglycan
gene. This subcomplex is functionally crucial since knocking
out the gene results in lethality [91], while conditional
knock-out mice revealed impaired synaptic plasticity in the
hippocampus, a major brain region involved in cognitive
function [92].
The α-dystroglycan is a receptor for ECM proteins, such
as laminin (α1a n dα2 chains) in striated muscles in associa-
tion with Dp427, agrin at the NMJ with utrophin, neurexins
in the CNS with brain Dp427, and most likely other forms of
laminin,perlecanandagrininbrain.Geneticlossordefective
glycosylation of brain α-dystroglycan abolishes its binding
activity to extracellular ligands, which results in critical
alterations of the basement-membrane and abnormal neural
migration during development. Hypoglycosylation of α-
dystroglycanduetomutationsinspeciﬁcglycosyltransferases
leads to the Walker-Warburg (WWS), Fukuyama (FCMD),
and muscle-eye-brain (MEB) syndromes, collectively known
as autosomal recessive congenital muscular dystrophies
(CMDS). These dystroglycanopathies result in a total disor-
ganization of the cortex associated with mental retardation
([93]f o rar e v i e w ) .
In muscles, β-dystroglycan binds calveolin-3 and an
adaptor protein called growth factor receptor-bound pro-
tein 2 (Grb2), suggesting participation in transduction
of extracellular-mediated signals. Grb2 may also regulate
interactions between β-dystroglycan and other partners of
the DGC in other tissues, such as with rapsin during
synaptogenesis at the NMJ [94], and with the focal adhesion
kinase(FAK)intheCNS[95],anonreceptortyrosinekinases
involved in neurite outgrowth, dendritic spine morphogene-
sis, and synaptic plasticity.
The muscle sarcoglycan subcomplex is composed of
four transmembrane glycoproteins, α-, β-, γ-, and δ-
sarcoglycans, which form heterotetrameric complex associ-
ated with dystroglycan and with a member of the tetraspan
family of proteins called sarcospan. Original ﬁndings sug-
gested selective expression in muscles and peripheral nerves.
However, recent studies revealed the existence of new
members of the sarcoglycan family in brain, ε-sarcoglycan
involved in myoclonus-dystonia syndrome and associated
with dopaminergic neurons, and ζ-sarcoglycan. Whereas
mutationsaﬀectingsarcoglycansleadtosevereformsofmus-
cular dystrophy, suggesting an important role in membrane
stability, their organization, function, and interaction with
the brain DGC remain unclear (reviewed in [90]).
Dystrobrevins and syntrophins are cytosolic components
of the DGC. Dystrobrevins are proteins of 87–94kDa
that are both dystrophin paralogs, due to their structural
homologies with the C-terminus of DMD-gene products,
and dystrophin-associated proteins due to their direct bind-
ing to the dystrophin/utrophin C-terminus through coiled-
coil motifs. The α-a n dβ-dystrobrevins, encoded by two
separate autosomal genes, occur as various isoforms in
many DGC-like complexes in both muscle and nonmuscle
tissues. Dystrophins and dystrobrevins can bind up to four
syntrophins, which in turn interact with a variety of key
membrane proteins (see below). Several other dystrobrevin-
binding proteins have been characterized, such as syncoilin,
dysbindin, and neuronal kinesin heavy chain 5A. The
dysbindin protein yielded much interest in recent research
[96], as it is produced by a schizophrenia-susceptibility gene.
Itisapartnerofthebiogenesisoflysosome-relatedorganelles
complex-1 (BLOC-1) thought to regulate the traﬃcking and
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of the synaptic vesicle cycle in central glutamatergic synapses
[97, 98].
Syntrophins are 59kDa adaptor proteins occurring as α-
, β1, β−2, γ−1, and γ−2 isoforms. They contain a PDZ
domain enabling associations with a variety of proteins
involved in critical cellular functions in CNS (reviewed in
[90]), including neuronal nitric oxide synthase (nNOS) and
manytransmembraneproteins,suchasthewateraquaporin-
4, potassium Kir2 and Kir4.1, and voltage-gated sodium
channels, as well as synaptic proteins like neuroligins,
calmodulin, and erbB-4 neuregulin receptors. Interactions
of the DGC with the scaﬀolding protein PSD-95 may occur
in neurons, due to the association of nNOS with this
protein. The potential binding of several syntrophins to one
DGC suggests that several of such interactions may occur
simultaneously in speciﬁc tissues or cell types, which places
syntrophin as a major player in the membrane organization
and signaling functions of brain DGC.
Much has been learned about DGC functions from
studiesofthemammalianNMJ,wheretheDGCaccumulates
in association with utrophin at the postsynaptic side during
early postnatal development and appears to be involved
in the process of neuromuscular synaptogenesis [94]. The
current model considers that agrin-mediated clustering of
AchR via muscle-speciﬁc tyrosine kinase MuSK does not
require the DGC. However, secondary interactions of DGC
with rapsyn, an eﬀector protein of MuSK, seem to be
required for AChR stabilization and synapse maturation,
as in mouse models lacking dystroglycan, utrophin, α1-
syntrophin, or α-dystrobrevin, the density of AChR clusters
isreducedattheNMJ[99–104].Analogiestothismodelhave
been recently evidenced in the CNS (see next section), sug-
gesting a general biological role for the DGC, in association
with distinct dystrophins and utrophins, in the stabilization
rather than targeting of membrane proteins during the
maturation and maintenance phases of synaptogenesis [89].
Despitemuchsimilaritiesbetweentheutrophin-glycoprotein
complex (UGC) and the DGC, functional diﬀerences have
been pointed out by several studies [105–107]. One example
is the gliovascular interface, where a speciﬁc Dp71-DGC
is expressed in the perivascular astrocyte endfeet, whereas
distinct UGC components associate with utrophin in the
facing endothelial cells. Both complexes may play a role
in BBB function. However, selective ablation of utrophin
or Dp71 only disrupts the corresponding UGC or DGC,
without aﬀecting the complex associated with the remaining
paralog [47], suggesting distinct functions for these separate
dystrophin-like complexes.
7. Role of Dystrophinsin the Mammalian Brain
The genesis of cognitive deﬁcits in DMD likely involves
cumulative inactivation of Dp427, Dp71, and Dp140. One
main goal of the past two decades has been to deﬁne the
genotype-phenotype correlations in patients and to specify
the localization and function of brain dystrophins. While
variable degrees of cognitive dysfunction were found in
DMD patients across IQ levels, the mutations aﬀecting Dp71
and Dp140 in addition to Dp427 emerged as aggravating
factors leading from moderate to severe mental retardation
[3]. Dp140 is abundant in the fetal brain, suggesting a
key role during brain development, whereas its presence
around blood vessels in the adult brain may play a role in
speciﬁc yet unidentiﬁed vascular-glial interactions [43, 44].
The function of Dp140 remains unknown and a mouse
model with selective disruption of this protein has not been
developed to date. In contrast, functional studies in several
dystrophin-deﬁcient mouse models have greatly increased
ourunderstandingofDp427andDp71functioninbrainand
uncovered the role of the DGC in critical cellular functions,
suggesting that the brain alterations in DMD mainly result
from the mistargeting of syntrophin-interacting proteins,
including key membrane receptors and channels involved in
neuronal and glial functions.
7.1. Full-Length Dystrophin (Dp427) Function. Most of our
current understanding of dystrophin function derives from
studies of the Dp427-deﬁcient mdx mouse. Although this
model lacks the full-length dystrophins in both muscle and
nonmuscle tissues, it does not exhibit extensive muscle
degeneration during the ﬁrst 6 months of postnatal life,
possibly due to eﬃcient muscle regeneration [108]. Mdx
mice however display abnormal motor behavior and coor-
dination [109] and reduced activity in open spaces [110].
Whether these deﬁcits result from muscle wasting or rather
reﬂect impaired forebrain or cerebellar functions remains an
open question. Noncognitive behavioral disturbance, such
as enhanced defensive freezing responses after restraint, has
also been shown in mdx mice suggesting altered amygdala
function [40]. Although the motor and emotional defects
in this model could inﬂuence the animal’s performance in
cognitive tests, analyses of speciﬁc behavioral parameters
in various paradigms allowed our group to characterize
mild but speciﬁc memory deﬁcits in mdx mice, part of
which likely involves brain structures that include the
hippocampal formation. While encoding of new experiences
and learning capabilities are globally preserved [111, 112],
mdx mice show slower learning in bar-pressing tasks and
impaired retention performance at long delays in several
tests involving recognition and spatial memories [110, 113–
116], which suggests a selective role for dystrophin in the
consolidation or expression of speciﬁc forms of long-term
memory.
Given the crucial role of synaptic plasticity in learning
andmemoryprocesses,thequestionthenaroseastowhether
altered synaptic function could explain the memory deﬁcits
in mdx mice. The early ﬁnding that CA1 hippocampal neu-
rons in mdx mice are more susceptible to hypoxia-induced
reduction in neurotransmission [117] suggested a critical
role for dystrophin in synaptic function. Despite changes
in the distribution of neuronal cells in speciﬁc cortices
[118], we did not ﬁnd gross histological abnormalities in
brains of mdx mice [119]. Current hypotheses consider
that the brain alterations are most likely located at the
cellular level, and there is now ample evidence that the
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expressing dystrophin. In Purkinje cells of cerebellum, mdx
mice display reduced heterosynaptic long-term depression
(LTD) of neurotransmission [120], whereas homosynaptic
LTD is enhanced [121]. In the hippocampus of the mdx
mouse, we found that NMDA receptor-dependent short-
(STP) and long-term potentiation (LTP) as well as LTD
are all abnormally enhanced in the CA1 dendritic layer
[110, 112, 115]. Hence, there are critical alterations of long-
term synaptic plasticity in these two brain regions when
dystrophin is missing.
Although various biochemical, physiological, and bioen-
ergetics abnormalities have been reported in brains of mdx
mice ([122, 123], for reviews), the main hypothesis to
explain brain dysfunctions in mdx mice is an alteration
of the inhibitory control of neurotransmission in principal
neurons. Indeed, dystrophin and dystroglycan colocalize
withα2-subunitofGABAA receptors (GABAA-R)incultured
hippocampalneurons,buttheirtargetingtothemembraneis
independent from that of GABAA-R and scaﬀolding protein,
gephyrin [124, 125]. In the adult CNS, dystrophin and DGC
are located in a subset of inhibitory synapses. Several studies
showed that the loss of dystrophin or dystrobrevins leads to
signiﬁcant reductions in the number and size of GABAA-R
clusters in hippocampus [126], cerebellum [109], and amyg-
dala [40]. Diﬀerent subunits of GABAA-R may be aﬀected in
distinct brain structures, for example, α1 in cerebellum and
α2 in hippocampus, suggesting that dystrophin is involved in
the clustering of subpopulations of GABAA-R at inhibitory
synapses. Together the current data suggest that dystrophin
is not essential during early GABAergic synaptogenesis but
rather stabilizes these receptors at a later stage, perhaps by
limiting their lateral diﬀusion outside the synapse through
neurexin-neuroligin dependent signaling [127, 128].
The number of GABAA-R and dystrophin clusters can be
m o d u l a t e di np a r a l l e li nam o d e lo ft e m p o r a ll o b ee p i l e p s y
in mice [129], suggesting a concomitant involvement of the
two proteins during the type of neural plasticity associated
with this pathological environment. However, compelling
evidence for functional interactions between dystrophin and
GABAA-R is still missing. The hypothesis however gained
support from recent electrophysiological studies conﬁrming
alterations of inhibitory function in mdx mice. First, the
potency of GABAA-R antagonist bicuculline to modulate
glutamatergic neurotransmission is reduced in mdx mice,
in both cerebellar and hippocampal neurons [130, 131].
In mdx cerebellar Purkinje cells, signiﬁcant reductions in
both the frequency and amplitude of spontaneous minia-
ture inhibitory postsynaptic currents (mIPSCs) have been
reported [130, 132], consistent with alterations of post-
synaptic GABAA-R function leading to reduced inhibitory
input. Studies in CA1 hippocampus provided opposite
results, showing increased mIPSCs frequency [133], which
suggests a higher probability of inhibitory synaptic release
in mdx mice in this structure. Our recent ultrastructural
study of CA1 hippocampal synapses revealed an increased
number of inhibitory synapses in mdx mice, which may
explain higher release probability at these synapses and
likely reﬂects systemic compensation for impaired GABAer-
gic function [119]. A study suggests that the increased
number of hippocampal inhibitory synapses results from
a compensatory increase in the number of parvalbumin-
positive GABAergic interneurons in this structure [134]. We
also demonstrated morphometric changes in the PSDs of
a subpopulation of excitatory synapses, which may account
for the sustained increase in CA1 synaptic eﬃcacy and
excitability. Interestingly, we also showed that the enhanced
hippocampal STP and LTD in mdx mice could be prevented
bybicuculline[131],suggestingacorrelationbetweenaltered
inhibitory function, changes in excitatory synapse morphol-
ogy, and abnormal CA1 hippocampal synaptic plasticity.
Furthermore, mdx mice have altered neuronal excitability
induced by AMPA/kainate subtypes of glutamate receptors
and increased susceptibility towards PTZ-induced kindled
seizures [135, 136], suggesting that dystrophin loss and
altered GABAA-R clustering globally compromise brain
excitatory/inhibitory balance.
Obviously, dystrophin does not solely play a structural
role in central synapses but likely participates to the ﬁne
tuning of critical plastic processes through regulation of
GABAA-R clusters at inhibitory synapses. Although other
classes of receptors may interact with dystrophin (e.g., [135,
137, 138]), this “dysfunctional inhibition” hypothesis seems
to be supported by studies in mdx mice and may account
at least in part for the brain physiological and cognitive
alterations associated with DMD [123].
Additionally, putative alterations of the brain vascular
permeability have been suggested by some studies, which
may also participate to behavioral deﬁcits in mdx mice.
Initial observations of mdx brains revealed severe alterations
of endothelial cells with open tight junctions surrounded
by swollen glial processes, decreased Dp71 and AQP4
expression, and enhanced vascular permeability suggesting
BBB breakdown [139, 140]. Follow-up studies suggested
that this results from hypoxic condition leading to the
activation of hypoxia inducible factor-1α contributing to
both BBB opening and compensatory angiogenesis, along
with changes in expression of matrix metalloproteinases,
nerve and vascular growth factors [141, 142], hence the
hypothesis that a progressive decline in respiratory function
duetomuscledegeneration[143]couldworsenthebrainand
cognitive impairments in advanced DMD patients through a
reduction in cerebral oxygenation and BBB disruption.
7.2. Dp71 Function. T h eD p 7 1 - n u l lm o u s e[ 144]d o e sn o t
have overt muscle pathology or motor impairment and
hence constitutes an appropriate model to assess the role of
Dp71 in the mammalian brain. Our group recently showed
thatDp71-nullmicedisplayselectivebehavioraldisturbances
characterized by reduced exploratory and novelty-seeking
behavior, mild retention deﬁcits in inhibitory avoidance,
and impairments in spatial learning and memory, suggesting
that dysfunction of this protein may participate to the
genesis of mental retardation in DMD [51]. As in other
mouse models of inherited mental retardation ([145]f o r
a review), the deﬁcits are correlated with abnormal exci-
tatory synapse organization and function. Dp71-null mice
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synaptic plasticity in the CA1 hippocampal subﬁeld and
have a reduced density of excitatory synapses. In Dp71-null
cultured neurons, abnormally large clusters of PSD-95 were
evidenced, suggesting that altered synaptic function may
result from a disorganization of this major signaling protein
involved in the clustering of glutamate receptors in the PSDs.
The cellular and molecular bases of these alterations
seem complex, since Dp71 has an apparent expression in
both glial and neuronal cells. Its subcellular expression and
putative binding partners suggest multiple functions. First,
Dp71showsamajorexpressionattheglial-vascularinterface,
that is, in perivascular astrocyte endfeet [47, 50], suggesting
a role in BBB function. Mice lacking α-syntrophin [146]o r
Dp71 [147, 148] have mistargeted aquaporin (AQP4) water-
permeable channels and altered water homeostasis possibly
due to impaired assembly of a speciﬁc Dp71-associated com-
plex.ThroughPDZ-mediatedinteractionwithα-syntrophin,
the glial DGC also associates with inwardly rectifying K+
channels(e.g.,Kir4.1)involvedinsiphoningK+ ionsreleased
into the extracellular space after neuronal excitation [149,
150]. It is hypothesized that laminin-dependent aggregation
of both Kir4.1 and AQP4 channels is mediated by the Dp71-
DGC in brain astrocytes [151]. This suggests multiple roles
for Dp71 in glia, including regulation of water homeostasis,
blood-neural barrier function and K+ buﬀering. Interest-
ingly, a comparable role has been evidenced in M¨ uller glial
cell end-feet in the retina, where Dp71 also serves as an
anchor for Kir4.1 and AQP4 channels [77]. The Dp71-null
retina thus constitutes an original model to assess Dp71
glial function in the CNS, as functional alteration of M¨ uller
cells is an early hallmark of most retina diseases. Studies
in this model have shown that Dp71 is crucially implicated
in the maintenance of potassium and water homeostasis,
as well as in the regulation of retinal vascular permeability
[152]. Despite a clear dysfunction of blood-retina barrier, no
alteration of visual function was observed in the Dp71-null
mice [153], suggesting that such Dp71-dependent defects are
compensated or do not induce major functional outcomes.
The presence of BBB alterations in the brain of Dp71-null
mice remains unclear. The selective loss of Dp71 appears
associated with altered BBB osmosensitivity in particular
brain structures but defective vascular permeability has
not been demonstrated [148, 154] and there is no clear
evidence that AQP4 depletion could aﬀect this function
[155]. However, because astrocytic functions of AQP4 and
Kir4.1 channels may contribute to neuronal function and
dysfunctionalplasticitybyregulatingthesynapticmicroenvi-
ronment in response to increased neuronal activity, putative
contribution of Dp71 to intercellular communication at the
neuron-glial and/or glial-vascular interfaces could explain
some of the neurological alterations associated with loss-of-
function mutations.
Additionally, we showed that a pool of Dp71 colocalizes
with key signaling proteins at glutamatergic synapses in
cultured neurons, and that Dp71 and DGC members from
adult-rodent brain extracts co-immunoprecipitate with sev-
eral signaling and scaﬀolding proteins associated with glu-
tamate receptors (NMDAr, AMPAr) in excitatory synapses
[51]. This is in agreement with several reports showing Dp71
expression in various neuronal-cell types [49, 156–158]a n d
in adult-brain PSDs [50]. However, as other studies failed
to detect DGC components in excitatory synapses in vitro
(e.g., [125]), the speciﬁc binding partners of the neuronal
and/or synaptic pool of Dp71 need to be further speciﬁed
and putative expression in inhibitory synapses cannot be
ruled out.
Dp71 is potentially involved in a variety of brain
physiological functions in both glia and neurons, suggest-
ing multifactorial eﬀects of loss-of-function mutations on
cognitive functions. Understanding the relevance of each
Dp71-dependent process to the physiological and behavioral
phenotypes associated with DMD is a major challenge for
future research. As the neural basis of mental retardation
in DMD results from the combined loss-of-function of
all dystrophin gene products, the brain alterations likely
encompassglialaswellassynapticdysfunctionsinvolvingthe
GABAergic and glutamatergic systems.
8. Role of Utrophins in the Mammalian Brain
Utrophins have not been directly implicated in any known
genetic disease. However, they show speciﬁc patterns of
expression in a variety of tissues and loss-of-function in mice
suggest a role in selective cellular functions. As mentioned
above, most of our knowledge on utrophin function comes
fromstudiesofitsroleattheneuromuscularsynapse.Studies
in utrophin-deﬁcient mice revealed a reduction in the
number of postsynaptic-membrane folds and acetylcholine
receptorsattheNMJ.Thesemiceareviableandshownosign
of muscular weakness and no compensation by dystrophin
expression. Moreover, dystroglycan and dystrobrevin expres-
sion remains largely unaﬀected suggesting that utrophin
is dispensable for assembly of the DGC but contributes
to proper maturation of the postsynaptic apparatus at the
NMJ [99, 100]. In contrast, mice lacking both dystrophin
and utrophin exhibit a severe muscular dystrophy with
growth retardation and premature death [159, 160]. In
these mice, β-dystroglycan is downregulated at the NMJ,
whereas dystrobrevin and β2-syntrophin are undetectable.
Nonetheless, expression of laminin-β2, agrin, and rapsyn
is unaﬀected, indicating that postsynaptic diﬀerentiation
can occur, not only in the absence of both utrophin and
dystrophin but also when the DGC is largely disrupted.
Much less is known about the function of utrophin-
gene products in brain. Expression in choroids plexus and
brain vasculature suggests a role in the proper functioning of
the BBB. Utrophin-deﬁcient (Utrn−/−)m i c eh a v ed e c r e a s e d
expression of the associated UGC components in epithelial
cellsofchoroidsplexusandendothelialcellsofmicrovascula-
ture,indicatingthatutrophinisrequiredforproperassembly
of the brain UGC [47]. However, no gross morphological
changes were observed in these structures in Utrn−/− mice
and the role of UGC is still unclear.
A possible role for utrophin in a subset of neurons
remains to be investigated. The pattern of utrophin expres-
sion around the soma of neurons is at variance with the
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suggesting that utrophin provides structural support for
neuronal membranes, whereas dystrophin is a component
of inhibitory synapses. Interestingly, very strong utrophin
immunoreactivitywasreportedseveralweeksafterinduction
of morphogenic changes in granule cells of the dentate
gyrus in an experimental model of temporal lobe epilepsy,
which suggested that utrophin contributes to protect CNS
neurons against pathological insults via long-term structural
stabilization of their membranes [161].
The localization and functional characterization of the
short C-terminal forms of utrophin is still at its infancy,
although several studies suggested their participation in
compensatory mechanisms in dystrophin-deﬁcient tissues
[78, 162, 163]( s e en e x ts e c t i o n ) .
9. Therapies for DMD: From Muscle to Brain
ThelastdecadesofresearchontherapeuticsforDMDyielded
a range of options to alleviate muscular dystrophy and/or
partly correct the cellular alterations resulting from congen-
ital loss of dystrophin. From pharmacological intervention
to gene therapy, several approaches might be translated to
brain, with the hope to progress toward treatments that
could alleviate both the muscular and cognitive alterations
in DMD.
Numerous pharmacological treatments have been con-
sidered to ameliorate the dystrophic-muscle phenotype in
DMD. Some of them enabled partial compensation of
speciﬁc physiological alterations. For example, blockade
of calcium channel and inhibition of calpain-dependent
processes were used to maintain calcium homeostasis,
whereasinhibitionofmyostatinoradministrationofinsulin-
like growth factor provided signiﬁcant increases in muscle
strength and mass (reviewed in [164]). Steroid therapy
involving administration of Deﬂazacort or Prednisolone has
long been shown to be beneﬁcial and is currently applied
to the patients to reduce inﬂammation. Such treatments
are however mostly supportive, associated with side eﬀects
[165, 166], and do not provide means to correct the causes
of DMD. Also, speciﬁc treatments should be developed
to alleviate the cognitive deﬁcits in DMD and could be
used in combination with muscle medical management.
Pharmacological strategies could involve modulation of the
GABAergic function, shown to be altered in the brain of mdx
mice. Below we discuss recent advances made in the search
of eﬃcient therapeutics for DMD and their applicability to
brain therapies.
9.1. Muscle Stem and Progenitor Cell Therapies. Cellular
therapies to alleviate muscle degeneration can be divided
into two strategies. First, normal precursor cells (satellite
cells) can be introduced into dystrophic muscle to diﬀer-
entiate into new myoﬁbers, leading to a relocalization of
dystrophin at the muscle sarcolemma, as shown in mdx mice
[167]. However, this technique shows limited intramuscular
migrationandtriggersimmuneresponsesagainstintroduced
cells or against the dystrophin itself. These obstacles can be
partly overcome by immunosuppression, multiple injections
with high-titration cell suspensions, and diﬀerent other
technologies that improve myoblast transfer. This, however,
remains a harsh intervention that only permits restoration of
about 30% of dystrophin-positive ﬁbers (reviewed in [168]).
A second strategy relies on transplantation of bone marrow
or speciﬁc stem cells. Although this has a good potential to
regenerate dystrophic muscle [168, 169], it also comes along
with immunogenicity and generally hampers combination
withothertreatments.Moreover,celltherapiesplacedafocus
on muscle treatment and do not ﬁnd immediate application
to the brain alterations in DMD.
9.2. Exogenous Dystrophin Delivery. Regulated gene transfer
for ectopic expression of dystrophin cDNA has met with
little success and faces many obstacles including limited
vector delivery, construction instability, immunogenicity,
and poor control of protein expression levels. The large
size of the DMD gene, which cannot be cloned in viral
vectors, hindered the possibility to deliver a complete form
of dystrophin. Most experimental success has been achieved
using truncated dystrophin minigenes that give rise to
mini-dystrophin lacking part of the central rod domain.
Although this approach brought some hope to convert a
DMD phenotype into that of the milder BMD [170, 171],
progressisneededtoachievesystemicadministrationtotreat
all aﬀected tissues including the brain.
9.3. Modulation of Utrophins Expression. Full-length
utrophin has a high level of expression in foetal and
regenerating muscles. Interestingly, muscle necrosis in
mdx mice occurs only when utrophin expression level
falls down to adult level, that is, at the time it should
be replaced by dystrophin [67]. Hence, it has long
been considered that utrophin and dystrophin subserve
comparable functions during foetal development and
adulthood, and that maintaining utrophin expression in
adult dystrophic tissues could compensate for dystrophin
loss. In support of this hypothesis, utrophin expression
is spontaneously regulated in mouse models of DMD,
suggesting endogenous compensations. In mdx skeletal
muscles, Utrn-A is overexpressed and extends along the
sarcolemma, whereas Utrn-B expression is increased in
vascular elements [78]. In mdx cardiac muscles, Utrn-A is
also overexpressed [68], while in mdx diaphragm, the short
utrophin isoform Up71 and β-dystroglycan are upregulated
and accumulate in regenerating areas [163]. Spontaneous
upregulations also occur in nonmuscle tissues, such as in
Dp71-deﬁcient platelets [172], and most importantly in
brains of DMD mouse models [78, 112, 162]. Although
the upregulation of brain utrophins is a matter of debate
[39], a recent report shows that full-length utrophins are
overexpressed in the brain of Dp427-deﬁcient mdx mice;
yet their expression in distinct structures as compared to
dystrophin may not help functional compensation [78].
Interestingly, overexpression of Up71 and Up113, but not of
full-length utrophin, has been reported in the brain mdx3CV
mice lacking all dystrophin-gene products [162]. However
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in glial endfeet is not compensated [47]. Taken together
the data suggest that utrophins are involved in tenuous
compensatory processes but cannot fully replace dystrophin
function. While utrophin upregulation in muscles may
participate to the slow progression of myopathy in the mdx
model, a better understanding of the complex interplay
between dystrophins and utrophins is needed to deﬁne
speciﬁc targets for pharmacological approaches in the brain.
The potential of exogenous utrophin has been demon-
strated using transgene and viral vector administration [170,
173, 174]. Delivery of a microutrophin in mdx (Utrn−/−)
micehasbeenrecentlyachievedthroughintravenousadmin-
istration of a recombinant adeno-associated virus (rAAV).
This restored expression of the muscle DGC and improved
animals’ dystrophic phenotype [175]. The strategy however
faces similar diﬃculties as with dystrophin-gene transfer.
Therefore, alternative ways are currently being considered
to regulate endogenous utrophins rather than promoting
ectopic expression.
Several pharmacological strategies have been employed
in an attempt to regulate endogenous utrophins. First,
administration of L-Arginine, the substrate of NO synthase
(NOS), or that of NO donors like molsidomine has been
shown to upregulate utrophin in muscle ﬁbers in mdx mice,
torestructuretheirmusclephenotype,andtoreducenecrosis
and contraction-induced damages [176–178]. L-arginine
likely induces other beneﬁcial eﬀects in mdx muscles,
such as reversion of lipid patterns in muscle membrane,
reduction of inﬂammatory signals, decreased activity of
matrix metalloproteinase (MMP), and downregulation of
NFkappaB, which may or may not depend on utrophin
regulation [179–181]. There is no direct evidence that NO
ameliorates the mdx phenotype through upregulation of
utrophin. However, owing to the multiple actions of NO
and because NOS associates with the DGC in both muscle
and nonmuscle tissues, the potential of NOS modulation
t oi m p r o v eb r a i na l t e r a t i o n si nD M Ds h o u l db ec o n s i d e r e d .
In this vein, a recent study shows that upregulating nNOS
in muscles compensates altered neurogenesis in mdx mice
hippocampus [182], suggesting that some brain alterations
in this model might be secondary to the myopathy and/or to
associated metabolic dysfunctions.
Alternatively, utrophin’s promoter activity can be mod-
ulated by speciﬁc transcription factors, growth factors, or
activators of upstream pathways. The postsynaptic expres-
sion of Utrn-A is regulated by heregulin, a nerve-derived
signalling molecule of the neuregulin family, which acts on
the N-box motif of utrophin promoter via the GA-binding
proteins, GABPα and GABPβ [183]. This can upregulate
utrn-A and improve the mdx phenotype [184]. Heregulin
can pass through BBB and potentially act in the CNS [185].
Regulation by a calcineurin-dependent activation of the
Nuclear Factor of Activated T-cell (NFAT) also improves
the dystrophic phenotype [186–188]. Posttranscriptional
mechanisms [189] and their regulations by certain transcrip-
tion factors, such as the peroxysome proliferator-activated
receptor (PPARβ/δ)[ 190], have been recently uncovered
and may provide new scent towards therapeutic approaches
involving regulation of utrophin promoters.
9.4. Suppressing Mutations to Restore Dystrophin Expression.
While systemic administration is a main advantage of
pharmacological approaches, the risk for nonspeciﬁc actions
and side eﬀects remains a major drawback. The development
of new molecular tools allowed a change in the focus
of therapeutic strategies towards the correction of gene
anomalies to rescue the missing protein (reviewed in [191]).
Approximately 5%–15% of DMD cases are caused by non-
sense mutation in the dystrophin gene. A way to eﬃciently
rescuedystrophinexpressionusesaminoglycosideantibiotics
like gentamycin, which interfere with the ribosome ability
to recognize premature-termination codons (PTC) and thus
restore open reading frame [192, 193]. This however results
in long-term toxicity with few good-responder patients
[194]. New nonsense-codon suppressor molecules are being
developed [195], such as the non-aminoglygoside PTC-
readthrough compounds (e.g., PTC124) currently under
clinical trial in DMD boys [196, 197]. Putative applications
in brain therapy have not been explored and may depend
on molecules capacity to cross the BBB and long-term side
eﬀects.
Another approach arose from the observation that
spontaneous exon skipping may lead to the presence of
dystrophin-positiveﬁbersindystrophicmuscles.Hence,syn-
thetic antisense oligonucleotides (AONs) have been recently
used to redirect splicing of the dystrophin pre-mRNA and
induceskippingofthemutatedexon23thatcontainsthestop
codon in mdx mice, thus generating a truncated transcript
with restored open reading frame [191, 198]. In theory, exon
skipping and production of truncated dystrophins would
be applicable to a large subgroup of DMD patients as far
as truncation does not aﬀect critical C-terminal domains,
but the functionality of diﬀerent in-frame dystrophins needs
t ob ed e t e r m i n e di nf u t u r er e s e a r c h e s[ 198]. One most
often mutated exon in DMD is exon 51; a strategy based
on skipping of this exon is currently under trial using
two target molecules, 2-O-methyl-AON or PR0051 [199]
and morpholino AVI-4658 [200]. Intramuscular injection of
AONs safely enables reexpression of dystrophin. However,
highandrepeateddoses arerequiredforlastingexpressionof
dystrophin due to limited uptake through passive diﬀusion.
Several methods have been explored to enhance eﬃciency of
AONs delivery, including use of diﬀerent carriers (nanopoly-
mers, nanospheres) and conjugation to short arginine-rich
cell-penetrating peptides (CPPs) to increase cellular uptake
[201]. The capacity of AONs to pass through the BBB
is null. However, dystrophin rescue could be achieved in
brain of mdx mice by intracerebroventricular morpholino
injections, which resulted in beneﬁcial behavioural eﬀects
[40]. To circumvent problems related to the stability and
uptake of AONs, they can be linked to a modiﬁed U7
small nuclear RNA (snRNA) sequence, which is naturally
implicated in the splicing of histone-transcript and therefore
enables correctsubcellularlocalization. This construct,when
expressed in rAAV vectors, can drive long-term dystrophin
expression with low immunogenicity, good cellular tropism,
and transduction eﬃciency in various muscle and nonmus-
cle tissues. In mdx mice, intramuscular injection of a single
dose of rAAV2/1-U7 system is eﬃcient to skip exon 23, drive12 Journal of Biomedicine and Biotechnology
sustained therapeutic levels of rescued dystrophin, and cor-
rect muscular dystrophy [202]. This approach has recently
been further developed with the addition of binding sites
for heterogeneous ribonucleoprotein A1, to improve nuclear
targeting of mRNAs [203]. Speciﬁc rAAV serotypes also
display good neuronal tropism and transduction eﬃciency
in rodent brain tissue in vivo [204, 205], suggesting that they
may also be used to alleviate the brain alterations in DMD.
10. Conclusion
Viewed as a structural protein ensuring muscle membrane
stability in the 1980s, dystrophin is now considered as the
central component of a scaﬀo l do fp r o t e i n se x p r e s s e di na
variety of tissues including the brain, where it is involved
in the clustering of several membrane receptors and ion
channels and in the modulation of cellular signal integration
and synaptic plasticity. The last two decades of research on
DMD enabled major breakthrough into new and critical cel-
lular processes, such as the clustering of GABAARa tc e n t r a l
inhibitory synapses and the organization of the molecular
machinery involved in water and K+ homeostasis at the
glial-vascular interface. Despite major advances, the speciﬁc
contribution of each of the dystrophins to the genesis of
cognitive impairment in DMD needs further speciﬁcations.
Research on brain utrophins is still at its infancy, but
it may also favor the discovery of new mechanisms and
contribute to signiﬁcant progress in the search of eﬃcient
therapeutics for DMD. The rapid development of modern
pharmacologicalandmoleculartoolstomodulateexpression
oftheutrophin/dystrophinfamilyofproteinsbringshopefor
the future design of appropriate therapies that will treat both
the muscle and brain impairments associated with DMD.
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